Revolutionizing HIV Prevention with Long-Acting Injectable PrEP Webinar Series

HealthHIV and the National Coalition for LGBTQ Health announce, Revolutionizing HIV Prevention with Long-Acting Injectable PrEP, a SYNChronicity Webinar Series. The purpose of this three-part series is to provide timely information about the implementation of recently approved lenacapavir as pre-exposure prophylaxis (PrEP), to reduce the risk of acquiring HIV-1, in practice and to drive synchronicity among clinicians, navigators, and pharmacists.

Join HealthHIV on July 11th, 2025 at 12:00pm EDT for “Lenacapavir in Clinical Practice – A Primer for Clinicians,” the first webinar in the series. Faculty, including principal investigators from the PURPOSE trials, will review clinical data and delve into opportunities and challenges for the real-world implementation of lenacapavir as PrEP. This webinar will cover medication administration, managing side effects, potential drug interactions, and transitioning patients on or off lenacapavir as PrEP. Participants will be able to engage with faculty in a live Q&A.

Please note that continuing education credits are not available for this webinar.

Learning Objectives

• Summarize the key clinical trial data that supported FDA approval of lenacapavir for HIV prevention.
• Identify appropriate patient populations for lenacapavir as PrEP.
• Explain the administration process, dosing schedule, and monitoring requirements for lenacapavir as PrEP.
• Discuss practical implementation strategies, including counseling points, reimbursement, and barriers to uptake of lenacapavir PrEP.

Faculty

• Colleen Kelley, MD, MPH, Emory University
• Onyema Ogbuagu, MBBCh, FACP, FIDSA, Yale School of Medicine
• Hyman Scott, MD, MPH, Bridge HIV in the San Francisco Department of Public Health

Related Events

• 

  SYNC 2025

  October 14 – October 15